BioCanRx, Canada’s Immunotherapy Network, is a network of scientists, clinicians, cancer stakeholders, academic institutions, NGOs and industry partners working together to accelerate the development of leading edge immune oncology therapies for the benefit of patients. BioCanRx invests in translating Canadian technologies from the lab into early phase clinical trials, and addresses socio-economic considerations necessary for their adoption by health-care systems. The network is currently supporting a translational immune-oncology pipeline of adoptive cell therapy, oncolytic viruses. Members of the BioCanRx network can provide expertise in research translation, biomanufacturing, and clinical evaluation of immunotherapies.